Asthma is a chronic airway inflammatory condition characterized by breathing difficulty due to bronchial and mucosal inflammation, which reduces the patient's life quality, and needs continuous pharmacological treatments. Therefore, drug development for the treatment of asthma contributes to healthy life. It has been previously reported that Portulaca oleracea L. have beneficial effects such as anti‐cancer, anti‐oxidant. The compound of Portulaca oleracea L. extracts (CPL) is derivatives of compound isolated from Portulaca oleracea L. extract. The aim of present study was to elucidate whether CPL modulates the asthma and to study its possible mechanisms of action using ovalbumin (OVA)‐induced airway inflammatory mouse model, and cell‐based in vitro models. In mouse model, CPL treated groups were reduced airway constriction and immune cell infiltration in the lung. CPL treated groups were inhibited the release of β‐hexosaminidase, and the level of pro‐inflammatory cytokines in bronchoalveolar lavage fluid. Moreover, CPL treated groups were alleviated the level of immunoglobulin (Ig) such as IgE, OVA‐specific IgE, IgG1 and IgG2a in serum, and the level of pro‐inflammatory cytokines in the lung. These symptoms are associated with the immune response of mast cell, RBL‐2H3 cells were used to evaluate for the effecting mechanism of CPL. In RBL‐2H3 cells, pre‐treatment of CPL suppressed the release of histamine and β‐hexosaminidase, and the expression of pro‐inflammatory cytokines. Taken together, our findings suggest that CPL could facilitate the prevention or treatment of asthma‐like allergic inflammatory diseases.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.